Ionis Pharmaceuticals IONS Selling General And Administrative Expense
Selling General And Administrative Expense at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's selling general and administrative expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's selling general and administrative expense?
- Ionis Pharmaceuticals (IONS) reported selling general and administrative expense of $150.36M in Q1 2026.
- How has Ionis Pharmaceuticals's selling general and administrative expense changed year-over-year?
- Ionis Pharmaceuticals's selling general and administrative expense increased by 97.2% year-over-year, from $76.25M to $150.36M.
- What is the long-term trend for Ionis Pharmaceuticals's selling general and administrative expense?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's selling general and administrative expense has grown at a 20.6% compound annual growth rate (CAGR), from $186.35M to $393.87M.
- What does selling general and administrative expense mean?
- Covers the costs of supporting the business, including marketing, sales force compensation, legal, human resources, and other corporate overhead. These are essential operating expenses that do not directly relate to the production of goods.